Cargando…

Reply to “Bone morphogenetic protein's contribution to pulmonary artery hypertension”

Detalles Bibliográficos
Autores principales:	King, Tyler, de Caestecker, Mark, Lowery, Jonathan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093875/ https://www.ncbi.nlm.nih.gov/pubmed/27857855 http://dx.doi.org/10.4103/2152-7806.192635

Ejemplares similares

Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension
por: Caestecker, Mark De, et al.
Publicado: (2001)

Commentary: Bone morphogenetic protein's contribution to pulmonary artery hypertension: Should this raise concern for patients undergoing spinal fusions with bone morphogenetic protein?
por: Epstein, Nancy E.
Publicado: (2014)

Bone morphogenetic protein 9, and its genetic variants contribute to susceptibility of idiopathic pulmonary arterial hypertension
por: Guo, Kefang, et al.
Publicado: (2020)

Reply to the letter to the editor: Could the use of bone morphogenetic proteins in fracture healing do more harm than good to our patients?
por: Sier, Cornelis F. M., et al.
Publicado: (2011)

Abnormal Trafficking of Endogenously Expressed BMPR2 Mutant Allelic Products in Patients with Heritable Pulmonary Arterial Hypertension
por: Frump, Andrea L., et al.
Publicado: (2013)

The concern on clinical use of recombinant human bone morphogenetic protein-2
por: Wiwanitkit, Viroj
Publicado: (2011)

Recombinant human bone morphogenetic protein 2 labeled use in spinal surgery and sexual dysfunction
por: Rakovac, Marija, et al.
Publicado: (2011)

Reply: Homocysteine and Thrombophilia in Pulmonary Hypertension
por: Lian, Tian-Yu, et al.
Publicado: (2022)

A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives
por: Lowery, Jonathan W., et al.
Publicado: (2016)

Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling: A case report
por: Choi, Sun Ha, et al.
Publicado: (2019)

Tricuspid Regurgitation Improvement in Relation to the Amount of Pulmonary Artery Pressure Reduction: reply
por: Zoroufian, Arezou
Publicado: (2010)

Overdue to understand anticoagulation in pulmonary arterial hypertension
por: Parikh, Kishan S., et al.
Publicado: (2018)

Pulmonary arterial hypertension incidence in Latvia in 2019
por: Kaulins, Ricards, et al.
Publicado: (2022)

Pulmonary arterial hypertension due to antiphospholipid syndrome initially mimicking chronic thromboembolic pulmonary hypertension
por: Yeo, Jina, et al.
Publicado: (2022)

Pulmonary artery sarcoma presenting as chronic thromboembolic pulmonary hypertension (CTEPH)
por: Ampatzidou, Fotini, et al.
Publicado: (2023)

Association of plasma bone morphogenetic protein‐4 levels with arterial stiffness in hypertensive patients
por: Wang, Ning, et al.
Publicado: (2022)

Management of hospitalized patients with pulmonary arterial hypertension and COVID-19 infection
por: Sahay, Sandeep, et al.
Publicado: (2020)

Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway
por: Zhang, Zhaohua, et al.
Publicado: (2017)

BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series)
por: Frump, Andrea, et al.
Publicado: (2018)

Reply to “Pulmonary toxicity by oxygen and COVID-19”()
por: Belenguer-Muncharaz, A., et al.
Publicado: (2022)

Identification of a bone morphogenetic protein type 2 receptor neutralizing antibody
por: Gorrell, Ruthann E., et al.
Publicado: (2019)

Application of [18F]FLT-PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers
por: Botros, Liza, et al.
Publicado: (2021)

Reply: Prevalence of hypertension and prehypertension in schoolchildren from Central India
por: Patel, Ashish, et al.
Publicado: (2019)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Preoperative pulmonary artery hypertension as a risk factor: the tip of the iceberg
por: Engin, Mesut, et al.
Publicado: (2023)

In Reply: Probability of Reduced Follow-up Health Care Visits for Controlled Hypertensive Patients
por: Chamberlain, Alanna M., et al.
Publicado: (2023)

Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension
por: Mutlu, Zeynep, et al.
Publicado: (2016)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Reply: COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match?
por: Lee, Joshua D., et al.
Publicado: (2021)

In Reply
por: Lacouture, Mario E, et al.
Publicado: (2022)

An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension
por: Ryanto, Gusty R. T., et al.
Publicado: (2021)

Authors’ reply: role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
por: Agrawal, Vineet, et al.
Publicado: (2020)

Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis
por: Baghizadeh, Somayyeh, et al.
Publicado: (2016)

15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation
por: Ahn, Kyung Jin, et al.
Publicado: (2019)

Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension
por: De Gottardi, Andrea, et al.
Publicado: (2012)

Reply to Role and importance of journal reader: Scientific contribution of letter to editor
por: Das, Nikunja K., et al.
Publicado: (2023)

Reply
por: Lemmon, Gary W.
Publicado: (2023)

Use of recombinant human bone morphogenetic protein-2 (rhBMP-2) as an adjunct for instrumented posterior arthrodesis in the occipital cervical region: An analysis of safety, efficacy and dosing
por: Hamilton, D. K., et al.
Publicado: (2011)

Reply
por: Harahsheh, Ashraf S., et al.
Publicado: (2020)

Methodological Contributions about Systolic Pulmonary Artery Pressure
por: Uz, Omer, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o86d2lq9ivgps82l8pg5vo3joi